ruptions)... Q. No. 170...*(Interruptions)...* Q. No. 171... (*Interruptions) ...*

*167. [For *answer* vide {TO/. 31 intra] *168. *[For answers* vide co/. 31 infra] *169. [For *answers* vide *col.* 32 infra] *170. *[For answers* vide co/. 32 infra]

*171. *[For answers* vide *col.* 33 infra]

Seminar on the development of wind energy

172. SHRI S. S. AHLUWALIA: Will the Minister of ENERGY be pleased to state:

(a) whether any seminar on the development of wind energy was held in New Delhi during the current year;

(b) if so, what were the issue$_s$ discussed and suggestions made in the seminar and the decision of Government on each of the issues discussed;

(c) whether Government propose to implement some of the suggestions made at the seminar; and

(d) if so, what are the details thereof and if not, what are the reasons therefor?

THE MINISTER OF ENERGY (SHRI VASANT SATHE): (a) and (b) An American Wind Energy Association Trade Mission organised a symposium on "US Wind Technologies" on 16th February 1988. In the symposium the Mission made presentations on overview of the wind power industry in USA which also included their experience on promotional policy, implementation and technical performance of wind turbines with special reference to wind farms for power generation. According to the papers presented, 1400 MW of wind farm capacity based on nearly 17000 grid connected wind electric generators has been installed till 31.12.1987 in the wind farms in Cal-fornia, U.SA. Technical information on various US products and services in the area of wind technology were also presented.

(c) and (d) No specific suggestions or recommendations were made in the symposium. However, information on their experiences have been taken note of, in connection with the programme which Government had itself launched to harness wind energy in the country.

श्री वसंत साठे : आपोजीशन हवा निकल गई । ...(**व्यवधान**)... बर्ताव जो है यह हवा आप की निकल गई है ...(**व्यवधान**)...

हम यहां बिजली की बात कर रहे हैं बिजली दिलाने की बात कर रहे हैं... ...(**व्यवधान**)...

.....ये तमाशा क्वश्चन आवर के बाद भी कर सकते थे...(**व्यवधान**)... ये तमाशा 12 बजे भी कर सकते थे...(**व्यवधान**)...यह सवाल पूछने का वक्त है और उन सवालों का जवाब देने के लिये हम यहां पर हैं ।... (**व्यवधान**)

MR. CHAIRMAN: Question No. 173. *(Interruptions)* Question No. 174. *(Interruptions)*

*173. *[For answer* vide *col.* 34 infra] *174. *[For answer* vide col. 36 infra]

Fric$_e$ Control of Bulk Drugs

*175. SHRI RAJNI RANJAN SAHU:f DR. (SHRIMATI) SAROJINI MAHISHI:

Will the Minister of INDUSTRY be pleased to state:

(a) the names of bulk drugs exempted from price control which are being produced in the country from penultimate and intermediate stages alongwith the names of intermediates/ penultimates;

(b) since when each such drug is being produced from intermediate and penultimate stage;

(c) the names of the bulk drugs which are allowed for import under OGL as per current import policy;

f The question was actually asked on the floor of the House by Shri Rajni Ranjan Sahn.

(d) what is the CIF price of each such drug per kg.;

(e) whether it is a fact that drug companies have submitted break up of prices of these drugs;

(f) if so, what are the names of those drugs; and

(g) what is the foreign exchange involvement in production of on© kg. of each of these bulk drugs?

THE MINISTER OF INDUSTRY (SHRI J. VENGALRAO); (a) to (g) A statement is laid on the Table of the House.

Statement

4 a) and (b) There are about 225 Scheduled & Non-scheduled bulk drugs produced in the country. Information available regarding some of these drugs are given in the enclosed Statement-I (See below)

(c) Information to the extent avail able is given in the enclosed State. ment-II *(See* below)

(d) and (g) CIF price & Foreign Exchange involvement in production are not monitored by this Department Information given by Companies do not include foreign exchange compo nent.

(e) and (f) Information to the ex tent available is given in the enclos ed Statement-lH.

Statement-I

Sl. No.	Name of Bulk drugs	Stage of Manufa-cture production	Date of licence
1	2	3	4
1	Vitamin 'A' Acetate and Palmitate	Basic	1958 & 1965
2	Chlordiazepoxide	Inter	1972
3	Sulphamethoxazole	Inter	1972
4	Vitamin 'E' Dotocophery (Acetate NF Grade)	Inter	1972
5	Tetanus Antitoxin	Basic	1976
6	FMD Vaccine,	Basic	1986
7	Hemaccel Scerile (Tzilor-made Protein)	Basic	1965
8	Tolbutamide	Inter	1959
9	Prenylamine Lactate	Inter	1974
10	Procaine HCL	Basic	
11	Benzocaine	Basic	1962
12	Pyrolidinomethyl Tetracycline	Inter	1963
13	Piperiding Ethyl Chloride HCL	Inter	1976
14	Novalgin Calcium	Inter	1975
15	Sodium Salt of N-4-Methyl Benzene Sulfonyl Carbamnic Acid Methoxy Ethyl Ester,	Inter	1975

1	2	3	4
16	Buclosamide	Inter	1975
17	Vitamin 'A' Palmitate	Basic	1971
18	Megestrol Acetate	Inter	1972
19	Meclazine HCL	Inter	1972
20	Meclazine HCL	Basic	1977
21	Calcium Sennosides	Basic	1975
22	Trichloro Ethyl Phosphate	Basic	1965
23	Betaionone (Drug Intermediate)	Basic	1974
24	Chlorphensin	Inter	1970
25	Mephenesin	Basic	1970
26	Ethynyl Oestradiol	Inter	1963
27	16-DPA (Drug Intermediate)		
28	LYN-Estrenol	Basic	1966
29	Ethynyl Estradiol 3-Methyl Ether (Mestranol)	Basic	1966
30	Methyl Testosterone	Basic	1962
31	Methanedionone (Dianabol)	Basic	1974
32	Estradiol/Estradiol Propionate	Basic	
33	Ethynyl Estradiol	Basic	1966
34	Progesterone	Basic	1962
35	Testosterone/Propinonate/Valerinate Undecylenate	Basic	1963
36	Phanquone (Entobex)	Inter	1972
37	Phthalyl Sulphathiazole	Inter	1971 & 1974
38	3-Methyl Sulpha Pyrazone (Vesulong)	Inter	Do.
39	Formyl Sulphathiazole (Formazibasol)	Inter	Do.
40	Glucosthidine Sulphate (Ismalin)	Inter	1963
41	Cyclopenthiside (Gavidrex)	Inter	1963
42	Sulpha Somidine (Elkosin)	Inter	1974-1971
43	Calcium Coramine	Inter	1971
44	Antrenyl (Oxyphenonium Bromide)	Inter	1971
45	Halothane	Basic	1974
46	Petmosol	Do.	Do.
47	Phenothiazine	Do.	Do.
48	Clofibrate	Do.	Do.
49	Propranolon HCL	Do.	Do.

1	2	3	4
50	Primidone	Inter	
51	Hexachlore Ethane	Basic	1974
52	Calcium Gluconate	Basic	1956
53	Calcium Lactobionate	Basic	1960
54	Ferrous Gluconate	Basic	1960
55	Calcibronate	Basic	
56	Magnesium Gluconate	Basic	1965
57	Intestopan Substance	Inter	1965
58	Active Principles of Senna	Basic	1967
59	Active Principles of Belladonna	Basic	1967

Statement-II

WJst of some bulk drugs under OGL.

1. Amobarbitol
2. Amoxacillin Sodium
3. Amphetamine Sulphate
4. Barbitol
5. Betamethasone and its salts
6. Bronidiol (2-Bromo-2-nitro prO-pane-l-2-Dion)
7. Calcium gluconate, injectable grade
8. Cephalexin
9. Chloramphenicol stearate and chloramphenicol sodium succinate
10. Chlorhoxidine base
11. Chlorpheniramine maleate
12. Chloroquine Sulphate
13. Cortisene acetate
14. Cyclobarbitol
15. Betamethasone
16. Dextran
17. Dextroamphetamine and itg salts
18. D menhy drinate
19. Dimethyl chloroltetracycline
30. Diphenhydramine hydrochloride
21. Drugs/Drug intermediate not in other categories specified.
22. Ephedrine Hydrochloride
23. Drythromycin ethyl succinate.
24. Estradiol benzoate
25. Ethyinyl estradiol
26. Ethisterone
27. Frusemid (Furosemide)
28. Glutethimide
29. Griseafulvin
30. Halothane including Halothane iff bottles
31. Hydrocortisone
32. Hyrdocortisone acetate
33. Indomethacin
34. Kanamycin
35. Levamisole Hcl.
36. Nitrazepam
37. Oxytocin
38. Panthenolg
39. Penotadartritol
40. Pethidine Hydrochloride
41. Phenetoin Sodium/Diphenyl Hy-dantoin
42. Pheniramine maleate
43. Piprazine (Diethylene diamine) anhydrous hezahydrate.
44. Prednisolone
45. Primidone
46. Procaine hydrochloride
47. Propantheline bromide
48. Pyrental Pamoate
49. Salicylicacid including 1 sodium salicylate 1
50. Secobarbitone
51. Secobarbitone Sodium.

Statement-Hi

S. No.	Name of Company	Bulk Drugs
)'.	Merind	. Yit. S12 (Cyno), Vit. B12 (Hydrocy)
1.	Glindia	. SoLtal Hcl, Vitamin A Pal.
3,		
	Alchem International	. Santonine
4,	E. Nerck .	. Rutin NF XI
5,	9.G. Pharmaceuticals	. Niconmalone I.P.
6.	Serum Ind.	. Tetanus, Anti toxine
T.		N.N. Nydroxy methyl Carlemide, Ferrous Calcium Citrate
S.	Weyths .	. Hydroxy Progedrong Caproate and iostanolone, Methyl testorons, Testonstecone enanthali, Testosterone, Tropionate, Tectosterone Progestrone, acetoxy Progesterone Pure, Prednisone, Tcstostesene Undeconeti
9.	Roche Products .	. . DL-L Tocopherol acetate NFH Grade, Vitamin A
10.	Bochringer Knoll	. Octlnum base, Octinum Mucate. Soveltol Sall-cyclate, Octinum D-AmidosuIoho-iatie Sovento *I* Lactate Octinum D Mucate Octiniro Base Multi-fungin Leptazol.
L,	Bakul Aromtics	. Caffeine
12.	KSDPL .	. Vitamin A
13.	Parke Davis	. Diphenhydremine Hcl
14.	Tamilnadu D dha	. Calcium Lactate, Lactic Acia. Danzzsle, Cisplatin
i3.	Rackitt & Colenm	. Tinidazole, Sucralfate
16.	IEL	. Tetmwl, Halothane, Propranolol, Primidone, Clofibrate
17,	Hindustan Ciba Geig}	' . . Diclofene Sodium Trimethoprim Lynestrenol, Methyl Testosterone Testestrone Testosterone Propionate, Testostrone Uudecylenate Tesfostrone Valerinate, Cestradiol Dipropionate Prcgostrone
18.	Maize Products .	. Dextrose Anhydrous, Oxprenolol Hcl.
19.	France Indian .	. Phenyl ethul Barbiturate of Quinidine
30,	Gjvt. opiun & \lkik	»ic Wjrks . Moronine Hel Hsl.. Morphine Salo'iate Morphine BPL, Djdaine Phosphate Colain? Sjlphate Ethyl Morphine & Hdro, Narcotine BP
£L	Sandoa	Cal. Glucoiate Oral Grade. Cal. Gluconate Ampule grade Calcium Lactobionate Oral Grade, Calcium Lactobionets amp. grade. Ferrous gluconate calcium Lactogluconate, Calcibronate.

S.No	Name of Company	Bulk Drugs
22.	Pfizer	Morantel Citrate
23.	Indo Pharma	Amphetamine SDU, Dicyelamine Hcl
24.	Euphoric	Tinidazole
25.	Bengal Immunities	Cholara Vaccine, Tetanus Antitoxim, 9 Amino Actidimu Sulbhodizine
26.	Associated drug	Caffenine, Isopropyl antipyrine
27.	Pefco	Caffenine
28.	Abbott	Pentolhal Sodium, Magaldrate
29.	Hoechst	Benzocaine, Procaine Oicl, Isopropyl Antipyrine, Tolbutamide.

(Interruptions)

THE MINISTER OF PARLIAMENTARY AFFAIRS AND THE MINISTER OF INFORMATION AND BROADCASTING (SHRI H. K. L. BHAGAT): please ask them to go to their seats.

MR. CHAIRMAN; Q. No. 176. *(Interruptions)*

Meetings of the Telephone Advisory Committees

•176. SHRI JOHN F. FERNANDES: Will the Minister of COMMUNICATIONS be pleased to state;

(a) whether Government have decided to convene Telephone Advisory Committee meetings after a period of six months, instead of the present three months;

(b) if so, what are the reasons for taking such a decision which will create a big gap between the consumer* and the Department leading to malpractices in the Department; and

(c) whether Government propose to Review thig decision and hold Telephone Advisory Committee meetings after a period of one month instead of three or six months for better functioning of this Department?

THE MINISTER OF STATE IN THE MINISTRY OF COMMUNICATIONS (SHRI GIRIDHAR GOMAN-GO): (a) to (c) A statement is laid or* the Table of the House.

Statement

(a) Yes, Sir.

(b) The decision to have meetings of Telecom. Advisory Committees once in six months was taken as austerity measure and in view of the need for curtailing expenditure. Thia was also due to the fact that Telecom. Advisory committees on the basis of Secondary Switching Areas under Telecom. District Engineers in the entire country in addition to 63 State/Union Territory/Telephone District Committees, are being formed. In these Secondary Switching Area Committees, the developmental and functional matters are discussed pertaining to Secondary Switching Areas only. Therefore, only policy matters concerning whole of State/Union Teri-tory/Te^hone District can be taken up by the Committees for which six months time interval is considered adequate.